Dr. Maloney on Future Treatment With CAR T-Cell Therapy

David G. Maloney, MD, PhD
Published: Friday, Nov 03, 2017



David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Patients need to be referred to treatment with CAR T-cell therapy at the appropriate time, states Maloney. The results will continue to be more beneficial as the studies move earlier in the disease course.

According to Maloney, it will take some time before CAR T-cell therapy is seen in oncology centers, as there is a learning curve associated with managing these patients.



David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Patients need to be referred to treatment with CAR T-cell therapy at the appropriate time, states Maloney. The results will continue to be more beneficial as the studies move earlier in the disease course.

According to Maloney, it will take some time before CAR T-cell therapy is seen in oncology centers, as there is a learning curve associated with managing these patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x